Low molecular weight heparin versus unfractionated heparin in patients with acute non-ST-segment elevation myocardial infarction undergoing percutaneous coronary intervention with drug-eluting stents
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Li, Yong-Jian | - |
dc.contributor.author | Rha, Seung Woon | - |
dc.contributor.author | Chen, Kang-Yin | - |
dc.contributor.author | Jin, Zhe | - |
dc.contributor.author | Wang, Lin | - |
dc.contributor.author | Ramasamy, Sureshkumar | - |
dc.contributor.author | Poddar, Kanhaiya L. | - |
dc.contributor.author | Minami, Yoshiyasu | - |
dc.contributor.author | Park, Ji-Young | - |
dc.contributor.author | Choi, Cheol Ung | - |
dc.contributor.author | Oh, Dong Joo | - |
dc.contributor.author | Jeong, Myung Ho | - |
dc.date.accessioned | 2021-09-06T23:25:48Z | - |
dc.date.available | 2021-09-06T23:25:48Z | - |
dc.date.created | 2021-06-18 | - |
dc.date.issued | 2012-01 | - |
dc.identifier.issn | 0914-5087 | - |
dc.identifier.uri | https://scholar.korea.ac.kr/handle/2021.sw.korea/109172 | - |
dc.description.abstract | Background: Whether low molecular weight heparin (LMWH) enoxaparin is equivalent to unfractionated heparin (UFH) in patients with non-ST-segment elevation myocardial infarction (NSTEMI) undergoing percutaneous coronary intervention (PCI) with drug-eluting stents (DES) remains unclear. Methods: A total of 2397 NSTEMI patients who underwent PCI with DES received either LMWH [n = 1178, subcutaneous enoxaparin 1 mg/kg, b.i.d., initiated after the patient's arrival and continued until 3-5 days after PCI plus reduced dose of UFH (50-70 U/kg) during PCI] or UFH (n=1219, 24,000 U/day infusion, initiated after the patient's arrival and continued until at least 48h after PCI). The bleeding events and clinical outcomes during in-hospital and at 8 months were compared. Results: Enoxaparin group had similar incidences of cardiac death, total death, and total major adverse cardiac events (MACE) at 8 months compared with UFH group. The incidences of major and minor bleeding events were also similar between the two groups. Multivariable Cox regression analysis showed that enoxaparin group had similar incidences of cardiac death [adjusted odds ratio (OR) 1.16, 95% confidence interval (CI) 0.64-2.10, p = 0.620], total death (adjusted OR 1.08, 95% CI 0.66-1.76, p = 0.760), and total MACE (adjusted OR 0.94, 95% CI 0.69-1.28, p = 0.692) at 8 months as compared with UFH group. Conclusions: Enoxaparin with reduced dose of UFH only during PCI as an adjunctive antithrombotic therapy in NSTEMI patients undergoing PCI with DES was safe and showed comparable 8-month clinical outcomes as compared with UFH alone. (C) 2011 Japanese College of Cardiology. Published by Elsevier Ltd. All rights reserved. | - |
dc.language | English | - |
dc.language.iso | en | - |
dc.publisher | ELSEVIER IRELAND LTD | - |
dc.subject | VON-WILLEBRAND-FACTOR | - |
dc.subject | DUAL ANTIPLATELET THERAPY | - |
dc.subject | HIGH-RISK PATIENTS | - |
dc.subject | UNSTABLE ANGINA | - |
dc.subject | ARTERY-DISEASE | - |
dc.subject | ENOXAPARIN | - |
dc.subject | METAANALYSIS | - |
dc.subject | THROMBOSIS | - |
dc.subject | OUTCOMES | - |
dc.subject | IMPLANTATION | - |
dc.title | Low molecular weight heparin versus unfractionated heparin in patients with acute non-ST-segment elevation myocardial infarction undergoing percutaneous coronary intervention with drug-eluting stents | - |
dc.type | Article | - |
dc.contributor.affiliatedAuthor | Rha, Seung Woon | - |
dc.contributor.affiliatedAuthor | Choi, Cheol Ung | - |
dc.contributor.affiliatedAuthor | Oh, Dong Joo | - |
dc.identifier.doi | 10.1016/j.jjcc.2011.09.005 | - |
dc.identifier.scopusid | 2-s2.0-84855186630 | - |
dc.identifier.wosid | 000299498200004 | - |
dc.identifier.bibliographicCitation | JOURNAL OF CARDIOLOGY, v.59, no.1, pp.22 - 29 | - |
dc.relation.isPartOf | JOURNAL OF CARDIOLOGY | - |
dc.citation.title | JOURNAL OF CARDIOLOGY | - |
dc.citation.volume | 59 | - |
dc.citation.number | 1 | - |
dc.citation.startPage | 22 | - |
dc.citation.endPage | 29 | - |
dc.type.rims | ART | - |
dc.type.docType | Article | - |
dc.description.journalClass | 1 | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.relation.journalResearchArea | Cardiovascular System & Cardiology | - |
dc.relation.journalWebOfScienceCategory | Cardiac & Cardiovascular Systems | - |
dc.subject.keywordPlus | VON-WILLEBRAND-FACTOR | - |
dc.subject.keywordPlus | DUAL ANTIPLATELET THERAPY | - |
dc.subject.keywordPlus | HIGH-RISK PATIENTS | - |
dc.subject.keywordPlus | UNSTABLE ANGINA | - |
dc.subject.keywordPlus | ARTERY-DISEASE | - |
dc.subject.keywordPlus | ENOXAPARIN | - |
dc.subject.keywordPlus | METAANALYSIS | - |
dc.subject.keywordPlus | THROMBOSIS | - |
dc.subject.keywordPlus | OUTCOMES | - |
dc.subject.keywordPlus | IMPLANTATION | - |
dc.subject.keywordAuthor | Enoxaparin | - |
dc.subject.keywordAuthor | Unfractionated heparin | - |
dc.subject.keywordAuthor | Acute non-ST-segment elevation myocardial infarction | - |
dc.subject.keywordAuthor | Drug-eluting stents | - |
dc.subject.keywordAuthor | Percutaneous coronary intervention | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
(02841) 서울특별시 성북구 안암로 14502-3290-1114
COPYRIGHT © 2021 Korea University. All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.